Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM2TU6W)

Drug Name
2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine Drug Info
Synonyms
5-Nonyloxytryptamine; 5-(Nonyloxy)tryptamine; O-nonylserotonin; 5-(Nonyloxy)-1H-indole-3-ethanamine; 157798-12-4; 2-(5-nonoxy-1H-indol-3-yl)ethanamine; CHEMBL97450; CHEBI:64149; 3-(2-aminoethyl)-5-nonyloxyindole; 1H-Indole-3-ethanamine,5-(nonyloxy)-; 2-[5-(nonyloxy)-1H-indol-3-yl]ethanamine; 5-(Nonyloxy)-tryptamine; Tocris-0901; NCGC00024858-01; Biomol-NT_000115; AC1L1C9C; GTPL106; SCHEMBL2335932; BPBio1_000133; AC1Q56M5; DTXSID4058653; CTK4C9475; ZINC1541570; BDBM50039947; AKOS030238973; 5-(nonyloxy)-tryptamine
Cross-matching ID
PubChem CID
1797
ChEBI ID
CHEMBL97450
CAS Number
CAS 157798-12-4
TTD Drug ID
D0C3EX

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.76 0.00e+0 19/20 (95%) MSMO1;SQLE;HSD17B7;...
Terpenoid backbone biosynthesis 2.15 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;FDPS;...
PPAR signaling pathway 1.95 1.78e-2 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Mitophagy 1.89 1.56e-2 56/68 (82.35%) FOXO3;ATF4;SQSTM1;...
Protein export -1.68 4.05e-2 17/23 (73.91%) SRP9;SRPRA;SEC63;...
Allograft rejection -1.71 3.37e-2 32/38 (84.21%) HLA-DPB1;HLA-DPA1;HLA-DRB1;...
Ribosome biogenesis in eukaryotes -1.77 1.40e-2 52/108 (48.15%) MPHOSPH10;XPO1;HEATR1;...
Asthma -1.79 1.44e-2 25/31 (80.65%) HLA-DPB1;FCER1A;HLA-DPA1;...
Oocyte meiosis -1.86 7.49e-3 90/129 (69.77%) PRKACA;INS;ADCY3;...
Hypertrophic cardiomyopathy -1.88 8.99e-3 81/90 (90%) SGCG;TNF;ITGA9;...
Systemic lupus erythematosus -1.91 8.43e-3 45/135 (33.33%) FCGR3B;SNRPD3;ACTN4;...
Dilated cardiomyopathy -1.92 7.49e-3 86/96 (89.58%) PRKACA;RYR2;ADCY3;...
Proteasome -2.08 0.00e+0 44/46 (95.65%) PSMA5;PSMC1;ADRM1;...
DNA replication -2.08 0.00e+0 34/36 (94.44%) LIG1;RPA2;POLA1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H